Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106274815 | 10627481 | 5 | F | 20140313 | 20160913 | 20141205 | 20160920 | EXP | CA-ROCHE-1500105 | ROCHE | 57.46 | YR | M | Y | 0.00000 | 20160920 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106274815 | 10627481 | 1 | PS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | 300 MG, ONCE IN EVERY FOUR WEEKS | U | S0042B,S0003B | 103976 | 300 | MG | SOLUTION FOR INJECTION | |||||
| 106274815 | 10627481 | 2 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 106274815 | 10627481 | 3 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 106274815 | 10627481 | 4 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 106274815 | 10627481 | 5 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 106274815 | 10627481 | 6 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 106274815 | 10627481 | 7 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 106274815 | 10627481 | 8 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 106274815 | 10627481 | 9 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 106274815 | 10627481 | 10 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0042B,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 106274815 | 10627481 | 11 | C | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | 0 | ||||||||||||
| 106274815 | 10627481 | 12 | C | VENTOLIN | ALBUTEROL SULFATE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 106274815 | 10627481 | 1 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 106274815 | 10627481 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 106274815 | 10627481 | Blood pressure increased | |
| 106274815 | 10627481 | Heart rate increased | |
| 106274815 | 10627481 | Nervousness | |
| 106274815 | 10627481 | Peripheral swelling | |
| 106274815 | 10627481 | Pruritus generalised | |
| 106274815 | 10627481 | Urticaria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 106274815 | 10627481 | 1 | 20130109 | 0 | ||
| 106274815 | 10627481 | 2 | 20130213 | 0 | ||
| 106274815 | 10627481 | 3 | 20140312 | 0 | ||
| 106274815 | 10627481 | 4 | 20141029 | 0 | ||
| 106274815 | 10627481 | 5 | 20141126 | 0 | ||
| 106274815 | 10627481 | 6 | 20150107 | 0 | ||
| 106274815 | 10627481 | 7 | 20150527 | 0 | ||
| 106274815 | 10627481 | 8 | 20150202 | 0 | ||
| 106274815 | 10627481 | 9 | 20160816 | 0 | ||
| 106274815 | 10627481 | 10 | 20160913 | 0 |